Table 1 Groups of mice immunized with different formulations of monovalent SARS-CoV-2 RBD vaccines.

From: Novel intranasal vaccine targeting SARS-CoV-2 receptor binding ___domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Group #

Riboxxim™ (μg)

Chitosan (μg)

RBD (μg)

RBD-C-CPE (μg)

1

50

–

10

–

2

50

–

10

–

3

50

10

10

–

4

–

–

10

–

5

50

–

–

–

6

50

10

–

–

7

50

–

–

10

8

–

–

–

10

9 (PBS)

–

–

–

–

  1. Nine groups of mice (n = 5 animals per group) were immunized with monovalent SARS-CoV-2 RBD vaccines of the indicated formulations. RBD-cCPE: receptor binding ___domain fused to the C-terminal polypeptide of the C. perfringens toxin (cCPE), which targets Claudin-4 on microfold (M) cells. Riboxxim™: Synthetic, double-stranded RNA TLR3/RIG-I agonist.
Back to article page